Literature DB >> 29705777

Delayed Ischemic Preconditioning Attenuated Renal Ischemia-Reperfusion Injury by Inhibiting Dendritic Cell Maturation.

Ting Zhang1,2, Nana Song1,3,4,5, Yi Fang1,3,4,5, Jie Teng1,3,4,5, XiaLian Xu1,3,4,5, Jiachang Hu1,3,4,5, Pan Zhang1, Rongyi Chen1, Zhihui Lu1, Xiaofang Yu1,3,4,5, Xiaoqiang Ding1,3,4,5.   

Abstract

BACKGROUND/AIMS: Even though delayed ischemic preconditioning (DIPC) has been reported to produce renal protection, the underlying mechanism remains poorly understood. We reported that a 15-minute renal ischemic preconditioning (IPC) 4 days before subsequent ischemia-reperfusion attenuated renal injury Kidney dendritic cells (DCs) are abundant in the renal tubulointerstitium and, depending on their status, can induce immune activation or tolerance. The aim of the present study was to investigate the role of DCs in IPC of the kidney.
METHODS: Mouse kidneys were challenged by transient brief episodes of sublethal ischemia followed by subsequent prolonged ischemia. DC abundance and maturation in the spleen and kidney were measured by flow cytometry and immunohistochemical staining. To confirm the function of mature DCs in the renoprotective effect of IPC on renal ischemia-reperfusion injury the A2 adenosine receptor (A2AR) antagonist SCH58261 was administered to stimulate DC maturation prior to assessment of renal functional and histological injury and the inflammatory reaction.
RESULTS: Compared with sham-operated animals, preconditioned mice had a reduced injury with less CD11c+ cells, lower levels of the pro-inflammatory cytokine IL-17 and reduced expression of the mature DC marker CCR7. Preconditioned mice also produced more of the anti-inflammatory cytokine IL-10. Both renal cells and splenocytes from these mice had more DCs (CD45+/CD11c+/F4/80-), but fewer of these DCs were mature (CD45+/CD11c+/ F4/80-/MHC-II+/CD80+) compared with those from sham-treated animals, suggesting that the immunomodulatory effect of renal ischemic preconditioning is both local and systemic. Additionally, injection of the A2AR antagonist SCH58261 reversed IPC-induced inhibition of DC maturation and mitigated the protective effect of preconditioning, suggesting that DC maturation contributes to immune cell-mediated ischemic preconditioning.
CONCLUSION: Our results show that DIPC of the kidney provides local and systemic immunosuppression by inhibiting DC maturation and hence mediates a renal protective effect.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acute kidney injury; Delayed Ischemic Preconditioning; Dendritic cells; Ischemia–Reperfusion

Mesh:

Substances:

Year:  2018        PMID: 29705777     DOI: 10.1159/000489366

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  4 in total

1.  Dynamics of circulating dendritic cells and cytokines after kidney transplantation-No effect of remote ischaemic conditioning.

Authors:  Marie B Nielsen; Kristian Ravlo; Marco Eijken; Nicoline V Krogstrup; Morten Bue Svendsen; Chadi Abdel-Halim; Mikkel Steen Petersen; Henrik Birn; Mihai Oltean; Bente Jespersen; Bjarne K Møller
Journal:  Clin Exp Immunol       Date:  2021-09-29       Impact factor: 4.330

Review 2.  Dendritic Cells as Sensors, Mediators, and Regulators of Ischemic Injury.

Authors:  Helong Dai; Angus W Thomson; Natasha M Rogers
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

3.  Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models.

Authors:  Jordi Guiteras; Laura De Ramon; Elena Crespo; Nuria Bolaños; Silvia Barcelo-Batllori; Laura Martinez-Valenzuela; Pere Fontova; Marta Jarque; Alba Torija; Oriol Bestard; David Resina; Josep M Grinyó; Joan Torras
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

4.  TRPC6 ameliorates renal ischemic reperfusion injury by inducing Zn2+ influx and activating autophagy to resist necrosis.

Authors:  Youmin Pu; Hongwen Zhao; Bingbing Shen; Qiang Zhou; Pan Xie; Xiongfei Wu
Journal:  Ann Transl Med       Date:  2022-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.